Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics reported positive Week 16 Phase 2b data for ORKA-001, showing 61% complete skin clearance in plaque psoriasis patients.
Share
Why It Matters
Oruka's new skin medicine worked better than a fake pill. When you see a medicine pass its tests, that's a sign the company might succeed.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.